The Prevalence of Multidrug-Resistant IAcinetobacter baumannii/I and Its Vaccination Status among Healthcare Providers

• Published in: Vaccines (Basel) 2023-06, Vol.11 (7)
• Main Authors: Elbehiry, Ayman, Marzouk, Eman, Moussa, Ihab, Mushayt, Yazeed, Algarni, Ahmad Abdullah, Alrashed, Osama Ali, Alghamdi, Khalid Saad, Almutairi, Naif Ahmed, Anagreyyah, Sulaiman Abdulaziz, Alzahrani, Anwar, Almuzaini, Abdulaziz M, Alzaben, Feras, Alotaibi, Meshal Abdullah, Anjiria, Suha Abdulaziz, Abu-Okail, Akram, Abalkhail, Adil
• Format: Article
• Language: English
• Subjects: Acinetobacter baumannii; Bacterial infections; Care and treatment; Diagnosis; Distribution; Drug resistance; Health aspects
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines11071171

There is growing concern among healthcare providers worldwide regarding the prevalence of multidrug-resistant Acinetobacter baumannii (A. baumannii). Some of the worst hospital-acquired infections, often in intensive care units (ICUs), are caused by this bacterial pathogen. In recent years, the rise in multidrug-resistant A. baumannii has been linked to the overuse of antimicrobial drugs and the lack of adequate infection control measures. Infections caused by this bacterial pathogen are the result of prolonged hospitalization and ICU stays, and they are associated with increased morbidity and mortality. This review outlines the epidemiology, risk factors, and antimicrobial resistance associated with A. baumannii in various countries, with a special focus on the Kingdom of Saudi Arabia. In response to the growing concern regarding this drug-resistant bacteria, fundamental information about its pathology has been incorporated into the development of vaccines. Although these vaccines have been successful in animal models, their effectiveness in humans remains unproven. The review will discuss the development of A. baumannii vaccines, potential related obstacles, and efforts to find an effective strategy against this pathogen.